The Potential for Genotoxicity, Mutagenicity and Endocrine Disruption in Triclosan and Triclocarban Assessed through a Combination of In Vitro Methods.

Journal: Journal of xenobiotics
Published Date:

Abstract

Triclosan and Triclocarban, preservatives widely used in cosmetics and other consumer products, underwent evaluation using a battery of new-approach methodologies in vitro (NAMs). Specifically, the Microplate Ames Test (MPF™ Test, Xenometrix, Allschwil, Switzerland) was employed to assess mutagenicity, the Comet assay in vitro on the HaCat cell line and the Mammalian Chromosome Aberration Test were utilized to evaluate genotoxicity, and the XenoScreen YES/YAS assay was applied to investigate endocrine disruption. The chemicals did not exhibit any positive responses for mutagenicity. However, the mammalian chromosome aberration test identified both chemicals as being positive for genotoxicity at 10 µg/mL. In the Comet assay, the percentage of DNA in the tail significantly increased in a concentration-dependent manner (at 5 and 10 µg/mL for Triclosan, at 2.5, 5, and 10 µg/mL for Triclocarban). The positive response depended on the increasing concentration and the duration of exposure. Triclosan, but not Triclocarban in any of the endocrine assays performed, indicated a potential for endocrine activity in the anti-estrogenic and anti-androgenic assays. The positive in vitro results detected were obtained for concentrations relevant to final products. The alarming findings obtained with the use of new-approach methodologies (NAMs) justify the current precautionary regulatory approach, limiting the use of these preservatives.

Authors

  • Jan Chrz
    Centre of Toxicology and Health Safety, National Institute of Public Health, Šrobárova 49/48, 100 00 Prague, Czech Republic.
  • Markéta Dvořáková
    Centre of Toxicology and Health Safety, National Institute of Public Health, Šrobárova 49/48, 100 00 Prague, Czech Republic.
  • Kristina Kejlová
    Centre of Toxicology and Health Safety, National Institute of Public Health, Šrobárova 49/48, 100 00 Prague, Czech Republic.
  • Danuše Očadlíková
    Centre of Toxicology and Health Safety, National Institute of Public Health, Šrobárova 49/48, 100 00 Prague, Czech Republic.
  • Lada Svobodová
    Centre of Toxicology and Health Safety, National Institute of Public Health, Šrobárova 49/48, 100 00 Prague, Czech Republic.
  • Lukáš Malina
    Department of Medical Biophysics, Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacky University in Olomouc, 779 00 Olomouc, Czech Republic.
  • Barbora Hošíková
    Department of Medical Biophysics, Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacky University in Olomouc, 779 00 Olomouc, Czech Republic.
  • Dagmar Jírová
    Centre of Toxicology and Health Safety, National Institute of Public Health, Šrobárova 49/48, 100 00 Prague, Czech Republic.
  • Hana Bendová
    Centre of Toxicology and Health Safety, National Institute of Public Health, Šrobárova 49/48, 100 00 Prague, Czech Republic.
  • Hana Kolářová
    Department of Medical Biophysics, Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacky University in Olomouc, 779 00 Olomouc, Czech Republic.

Keywords

No keywords available for this article.